Asia-Pacific Epigenetics Diagnostic Market, By Product (Reagents, Kits, Instruments & Consumables, Bioinformatics Tools & Enzymes), Technology (DNA Methylation, Histone Methylation, Chromatin Structures, Histone Acetylation, Large Non-Coding RNA & MicroRNA Modification), Type of Therapy (Histone Deacetylase (HDAC) Inhibitors, DNA Methyltransferase (DNMT) Inhibitors & Others), Application (Oncology, Cardiovascular Diseases, Metabolic Diseases, Immunology, Inflammatory Diseases, Infectious Diseases & Others), End User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs) & Others), Distribution Channel (Direct Tender & Retail Sales), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific) Industry Trends and Forecast to 2028.
Market Analysis and Insights: Asia-Pacific Epigenetics Diagnostic Market
Asia-Pacific epigenetics diagnostic market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 18.3% in the forecast period of 2021 to 2028 and is expected to reach USD 2,767.57 million by 2028 from USD 746.23 million in 2020. The high prevalence of chronic diseases and technological development in epigenetics field is likely to be the major drivers which propel the demand of the market in the forecast period.
The epigenetics diagnostic is the study of genetics, cellular and physical trait variations and developmental biology which is caused by the external environmental. This in turn affects genes and cellular ability to read genes without being affected by changes in genotype. The epigenetics changes result into changes in phenotype of organism rather than genotype, the underlying DNA and RNA sequence remains unchanged. The epigenetic changes are essential for development as they are dynamic and change with respect to environment.
The genetic expressions of organism are effected by epigenetics, which is making it the most crucial field of molecular biology and developmental genetics. Organizations, such as the National Center Institute, the National Institute of Health, and the International Human Epigenome Consortium, are funding and supporting research and development activities pertaining to the field of epigenetics. Epigenetics is also used to treat a variety of chronic diseases such as cancer, metabolic diseases, and others.
The Asia-Pacific epigenetics diagnostic market report provides details of market share, new developments, and impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.
Asia-Pacific Epigenetics Diagnostic Market Scope and Market Size
Asia-Pacific epigenetics diagnostic market is categorized into six notable segments which are based on product, technology, type of therapy, application, end user, and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of product, the Asia-Pacific epigenetics diagnostic market is segmented into reagents, kits, instruments & consumables, bioinformatics tools, and enzymes. In 2021, reagents segment is expected to dominate the market as there is increase in product launch of epigenetics reagents in the region.
- On the basis of technology, the Asia-Pacific epigenetics diagnostic market is segmented into DNA methylation, histone methylation, chromatin structures, histone acetylation, large non-coding RNA, and microRNA modification. In 2021, DNA methylation segment is expected to dominate the market as the DNA methylation technology is being used in a variety of epigenetics diagnosis of various diseases.
- On the basis of type of therapy, the Asia-Pacific epigenetics diagnostic market is segmented into histone deacetylase (HDAC) inhibitors, DNA methyltransferase (DNMT) inhibitors, and others. In 2021, histone deacetylase (HDAC) inhibitors segment is expected to dominate the market as it plays a major role in several biological processes, such as proliferation, cell cycle progression and differentiation. Histone deacetylase (HDAC) and their inhibitors can be used to post-translationally modify histones—the histone code that is read and recognized by other proteins to regulate gene expression.
- On the basis of application, the Asia-Pacific epigenetics diagnostic market is segmented into oncology, cardiovascular diseases, metabolic diseases, immunology, inflammatory diseases, and others. In 2021, oncology segment is expected to dominate the market due to high prevalence of cancer in Asia-Pacific region.
- On the basis of end user, the Asia-Pacific epigenetics diagnostic market is segmented into academic and research institutes, pharmaceutical and biotechnology companies, contract research organizations (CROs), and others. In 2021, academic and research institutes segment is expected to dominate the market as there is increase in funding of research activities by public-private partnership.
- On the basis of distribution channel, the Asia-Pacific epigenetics diagnostic market is segmented into direct tender and retail sales. In 2021, direct tender segment is expected to dominate the market due to escalation in marketing activities and improved customer services in Asia-Pacific region.
Asia-Pacific Epigenetics Diagnostic Market Country Level Analysis
Asia-Pacific epigenetics diagnostic market is analysed, and market size information is provided by country, product, technology, type of therapy, application, end user, and distribution channel.
The countries covered in the Asia-Pacific epigenetics diagnostic market report are Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific.
China is expected to dominate the market in Asia-Pacific, as the demand for epigenetics testing is increasing because of high prevalence of chronic diseases.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
The Presence of Advanced Technology and Strategic Initiatives Taken by Players are Creating New Opportunities in Asia-Pacific Epigenetics Diagnostic Market
Asia-Pacific epigenetics diagnostic market also provides you with detailed market analysis for every country's growth in a particular industry with products sales, the impact of advancement in the market, and changes in regulatory scenarios with their support for the epigenetics diagnostic market. The data is available for the historic period 2010 to 2019.
Competitive Landscape and Asia-Pacific Epigenetics Diagnostic Market Share Analysis
Asia-Pacific epigenetics diagnostic market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus related to epigenetics diagnostic market.
Some of the major companies providing the epigenetics diagnostic are PerkinElmer Inc., Diagenode, F. Hoffman-La Roche Ltd, EPICYPHER, Promega Corporation, QIAGEN, Pacific Biosciences of California, Inc., Epigenomics AG, Reaction Biology, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Merck KGaA, Illumina, Inc., ACTIVEMOTIF, Thermo Fisher Scientific, Inc., EpiGentek Group Inc., Enzo Life Sciences, Inc., GlaxoSmithKline plc., MDxHealth, Abcam plc and Salarius Pharmaceuticals, Inc. among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The strategic initiatives by market players and new technological advancements for epigenetics diagnostic are bridging the gap for variety of treatments.
For instance,
- In February 2020, Datar Cancer Genetics announced that it has participated in Apollo Cancer Conclave. This has helped the company to furnish correct knowledge about its oncology products in the market.
Collaboration, joint ventures, and other strategies by the market player is enhancing the company market in the dental instruments market, which also provides the benefit for the organization to improve their offering for epigenetics diagnostic market.
SKU-